Gene Therapy for Retinal Degeneration

Rajendra S. Apte

doi:10.1016/j.cell.2018.03.021

Gene Therapy for Retinal Degeneration

Rajendra S. Apte

Research output: Contribution to journal › Short survey › peer-review

25 Scopus citations

Abstract

Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF. Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF.

Original language	English
Pages (from-to)	5
Number of pages	1
Journal	Cell
Volume	173
Issue number	1
DOIs	https://doi.org/10.1016/j.cell.2018.03.021
State	Published - Mar 22 2018

Access to Document

10.1016/j.cell.2018.03.021

Fingerprint Dive into the research topics of 'Gene Therapy for Retinal Degeneration'. Together they form a unique fingerprint.

Cite this

@article{9418c3724e6f4464802ecbe65c237076,

title = "Gene Therapy for Retinal Degeneration",

abstract = "Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF. Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF.",

author = "Apte, {Rajendra S.}",

year = "2018",

month = mar,

day = "22",

doi = "10.1016/j.cell.2018.03.021",

language = "English",

volume = "173",

pages = "5",

journal = "Cell",

issn = "0092-8674",

number = "1",

}

TY - JOUR

T1 - Gene Therapy for Retinal Degeneration

AU - Apte, Rajendra S.

PY - 2018/3/22

Y1 - 2018/3/22

N2 - Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF. Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF.

AB - Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF. Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF.

UR - http://www.scopus.com/inward/record.url?scp=85044132232&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2018.03.021

DO - 10.1016/j.cell.2018.03.021

M3 - Short survey

C2 - 29570997

AN - SCOPUS:85044132232

VL - 173

SP - 5

JO - Cell

JF - Cell

SN - 0092-8674

IS - 1

ER -